NORTH AMERICA SODIUM-DEPENDENT GLUCOSE CO-TRANSPORTER 2 (SGLT2) MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

NORTH AMERICA SODIUM-DEPENDENT GLUCOSE CO-TRANSPORTER 2 (SGLT2) MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

The North America Sodium-Dependent Glucose Co-Transporter 2 (Sglt2) Market is expected to register a CAGR greater than 9% over the forecast period, 2022-2027.

COVID-19 significantly exacerbate Diabetes risks because the virus binds to pancreatic cells that produce insulin and could exert a toxic effect on them. In fact, they point out, studies of the earlier SARS-CoV-1 virus found that many infected patients had increased blood sugar. Drugmakers are rushing to advance potential treatments for the fast-spreading virus outbreak that has infected more people globally and so far, many were killed by the respiratory illness, according to a Reuters tally. SGLT2 inhibitors drug maker, AstraZeneca said “it is committed to finding new solutions to fight COVID-19 by investigating the application of new and existing medicines.”

An FDA-approved group of prescription drugs known as SGLT2 inhibitors is used in combination with diet and exercise to decrease blood sugar levels in persons with type 2 diabetes. SGLT2 inhibitors include canagliflozin, dapagliflozin, and empagliflozin as medications. They can be found as one-ingredient formulations or in mixtures with other diabetic medications like metformin. By encouraging the kidneys to eliminate sugar from the body through the urine, SGLT2 inhibitors reduce blood sugar levels. The FDA has not authorized SGLT2 inhibitors for use in individuals with type 1 diabetes because their safety and effectiveness in these patients have not been shown.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Key Market TrendsJardiance Drug Holds the Highest Share in The North America Sodium-Dependent Glucose Co-Transporter 2 (Sglt2) Market

An oral diabetic medication called Jardiance aids in blood sugar regulation. The way empagliflozin works is by facilitating the kidneys' removal of glucose from circulation. For individuals with type 2 diabetes mellitus, Jardiance is taken in conjunction with diet and exercise to enhance blood sugar management. In individuals with type 2 diabetes and heart disease, Jardiance is used to reduce the risk of mortality from a heart attack, stroke, or heart failure. Adults with heart failure can also take Jardiance to lower their risk of cardiovascular mortality and hospitalization for heart failure (when the heart is frail and unable to pump enough blood to the body's other organs).

The Jardiance group of products, managed in a partnership with Eli Lilly, sales up by 25.5% in the year 2021. Diabetes treatment is increasingly used to cut the risk of cardiovascular disease in diabetic patients and for the treatment of heart failure. Jardiance granted by FDA Breakthrough Therapy designation and FDA Fast Track designation. Submitted in the United States, and Japan in January 2022. The FDA granted priority review for adults with heart failure independent of left ventricular ejection fraction.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Sodium-Dependent Glucose Co-Transporter 2 (SGLT 2) Market Region.

The United States is Expected to Dominate the North America Sodium-Dependent Glucose Co-Transporter 2 (SGLT 2) Market

Due to its importance in glucose reabsorption, SGLT2 was identified as a promising pharmacological target in T2DM. While all SGLT2 inhibitors appear to be safe and effective for treating T2DM in patients, the most important difference among the individual agents is the uneven evidence base for use of these drugs as heart failure-specific therapy.

The United States is considered to be a premium market space for most pharmaceutical companies, as they can price their drug at a high price than the other countries and still have high sales. The country’s insurance policy, which reimburses close to 50% of the drug cost to the consumers, acts as a boon for pharmaceutical companies selling drugs. The United States is anticipated to dominate the market during the forecast period, owing to the rising prevalence of obesity in the Country.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Region.

Competitive Landscape

The market studied is consolidated with Janssen Pharmaceutical, Eli Lilly, AstraZeneca Pharmaceuticals, and Boehringer Ingelheim Pharmaceuticals holding a high market share, followed by regional manufacturers accounting for a relatively smaller share.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.